Menu
Search
|

Menu

Close
X

Homology Medicines Inc FIXX.OQ (NASDAQ Stock Exchange Global Select Market)

20.60 USD
+0.12 (+0.59%)
As of Sep 13
Previous Close 20.48
Open 20.34
Volume 49,023
3m Avg Volume 94,494
Today’s High 20.81
Today’s Low 19.67
52 Week High 31.80
52 Week Low 14.19
Shares Outstanding (mil) --
Market Capitalization (mil) --
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.50 Mean rating from 6 analysts

KEY STATS

Revenue (mm, USD)
FY19
1
FY18
4
FY17
0
EPS (USD)
FY19
-1.248
FY18
-1.509
FY17
-0.799
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.66
Price to Sales (TTM)
vs sector
--
7.91
Price to Book (MRQ)
vs sector
--
5.38
Price to Cash Flow (TTM)
vs sector
--
24.36
Total Debt to Equity (MRQ)
vs sector
--
14.55
LT Debt to Equity (MRQ)
vs sector
--
10.20
Return on Investment (TTM)
vs sector
--
14.48
Return on Equity (TTM)
vs sector
--
15.78

EXECUTIVE LEADERSHIP

Arthur Tzianabos
President, Chief Executive Officer, Director, Since 2016
Salary: $490,500.00
Bonus: --
W. Bradford Smith
Chief Financial Officer, Treasurer and Secretary, Since 2017
Salary: --
Bonus: --
Albert Seymour
Chief Scientific Officer, Since 2016
Salary: $386,948.00
Bonus: --
Tim Kelly
Chief Technical Operations Officer, Since 2018
Salary: $353,600.00
Bonus: --
Alise Reicin
Director, Since 2019
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

1 Patriots Park
BEDFORD   MA   01730-2343

Phone: +1781.3017277

Homology Medicines, Inc. is a genetic medicines company translating gene editing and gene therapy technology into treatments for patients with rare diseases. The Company is focused on developing a pipeline of new medicines that address and cure the underlying cause of monogenic diseases in the liver, central nervous system (CNS), bone marrow, lung and the eye. The Company’s lead product candidate, HMI-102 is a gene therapy for the treatment of phenylketonuria (PKU). Its PKU program is focused on adults using the gene therapy approach. The Company’s suite of 15 adeno-associated virus vectors (AAVHSCs) enables it to focus on a method of gene editing called gene correction. The Company’s diverse set of AAVHSCs allows it to precisely target, via a single intravenous injection, a wide range of disease-relevant tissues, including the liver, central nervous system, or CNS, bone marrow, lung, muscle and eye, across both modalities - gene editing and gene therapy.

SPONSORED STORIES